Maysa Abu‐Khalaf

3.3k total citations · 2 hit papers
91 papers, 1.8k citations indexed

About

Maysa Abu‐Khalaf is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maysa Abu‐Khalaf has authored 91 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 37 papers in Cancer Research and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maysa Abu‐Khalaf's work include Breast Cancer Treatment Studies (24 papers), Cancer Treatment and Pharmacology (21 papers) and Advanced Breast Cancer Therapies (18 papers). Maysa Abu‐Khalaf is often cited by papers focused on Breast Cancer Treatment Studies (24 papers), Cancer Treatment and Pharmacology (21 papers) and Advanced Breast Cancer Therapies (18 papers). Maysa Abu‐Khalaf collaborates with scholars based in United States, Italy and United Kingdom. Maysa Abu‐Khalaf's co-authors include Lajos Pusztai, Michael P. DiGiovanna, Anees B. Chagpar, Tara Sanft, Donald R. Lannin, Brigid K. Killelea, Erin Hofstatter, Suzanne B. Evans, Cary P. Gross and Nina Horowitz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Maysa Abu‐Khalaf

85 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of Financial Burden of Cancer on Survivors' Quality of Life

2014 360 citations Michael P. DiGiovanna, Lajos Pusztai et al. profile →
Social Determinants of Health and Cancer Care: An ASCO Policy Statement

2024 42 citations Maysa Abu‐Khalaf, Kira Bona et al. JCO Oncology Practice profile →

Peers

Maysa Abu‐Khalaf

ONCOL

PRM

Lola A. Fashoyin‐Aje United States

G. Pentheroudakis Greece

Paul Smith United Kingdom

Ray D. Page United States

Daniel M. Geynisman United States

Erin Hofstatter United States

Harpreet Singh United States

Richard J. Bleicher United States

Michael P. DiGiovanna United States

Neelima Denduluri United States

Lola A. Fashoyin‐Aje United States

Maysa Abu‐Khalaf

1.1k ×1.1

ONCOL

349 ×0.6

295 ×0.8

188 ×0.6

450 ×1.4

PRM

Citations per year, relative to Maysa Abu‐Khalaf Maysa Abu‐Khalaf (= 1×) peers Lola A. Fashoyin‐Aje

Countries citing papers authored by Maysa Abu‐Khalaf

Since Specialization

Citations

This map shows the geographic impact of Maysa Abu‐Khalaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maysa Abu‐Khalaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maysa Abu‐Khalaf more than expected).

Fields of papers citing papers by Maysa Abu‐Khalaf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maysa Abu‐Khalaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maysa Abu‐Khalaf. The network helps show where Maysa Abu‐Khalaf may publish in the future.

Co-authorship network of co-authors of Maysa Abu‐Khalaf

This figure shows the co-authorship network connecting the top 25 collaborators of Maysa Abu‐Khalaf. A scholar is included among the top collaborators of Maysa Abu‐Khalaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maysa Abu‐Khalaf. Maysa Abu‐Khalaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abu‐Khalaf, Maysa, et al.. (2024). Social Determinants of Health and Cancer Care: An ASCO Policy Statement. JCO Oncology Practice. 20(5). 621–630. 42 indexed citations breakdown →

Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations

Abu‐Khalaf, Maysa, Christos Hatzis, Elisa Baldelli, et al.. (2023). AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. npj Precision Oncology. 7(1). 18–18. 21 indexed citations

Silver, Daniel P., et al.. (2023). PARP Inhibitors for the Treatment of BRCA1/ 2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Hematology/Oncology and Stem Cell Therapy. 16(3). 186–196. 3 indexed citations

Lynce, Filipa, Matthew Blackburn, Christopher Gallagher, et al.. (2021). Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer. 127(19). 3622–3630. 14 indexed citations

Luo, Rui, Weelic Chong, Qiang Wei, et al.. (2021). Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. npj Breast Cancer. 7(1). 72–72. 26 indexed citations

Abu‐Khalaf, Maysa, et al.. (2018). Breast cancer patients with brain metastasis undergoing GKRS. Breast Cancer. 26(2). 147–153. 6 indexed citations

Foldi, Julia, Sarah S. Mougalian, Andrea Silber, et al.. (2018). Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer. Breast Cancer Research and Treatment. 169(2). 333–340. 14 indexed citations

Rodón, Jordi, José Alejandro Pérez Fidalgo, Ian E. Krop, et al.. (2018). Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 82(2). 285–298. 40 indexed citations

10.

Uppal, Guldeep, et al.. (2017). A Case of Carcinocythemia: De Novo Hormone Receptor-positive Metastatic Breast Cancer Presenting With Circulating Tumor Cells Mimicking an Acute Leukemia. Clinical Breast Cancer. 18(3). e295–e298.

11.

Varadan, Vinay, Hannah Gilmore, Kristy Miskimen, et al.. (2016). Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clinical Cancer Research. 22(13). 3249–3259. 75 indexed citations

12.

Hatzis, Christos, W. Fraser Symmans, Ya Zhang, et al.. (2015). Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research. 22(1). 26–33. 44 indexed citations

13.

Abu‐Khalaf, Maysa, Ingrid A. Mayer, Andrew R. Allen, et al.. (2015). A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.. Journal of Clinical Oncology. 33. 2 indexed citations

14.

Varadan, Vinay, Sitharthan Kamalakaran, Hannah Gilmore, et al.. (2015). Brief‐exposure to preoperative bevacizumab reveals a TGF‐β signature predictive of response in HER2‐negative breast cancers. International Journal of Cancer. 138(3). 747–757. 14 indexed citations

15.

Chang, Bryan, et al.. (2013). Prolonged Progression-Free Survival in a Patient With Triple-Negative Breast Cancer Metastatic to the Liver After Chemotherapy and Local Radiation Therapy. Clinical Breast Cancer. 14(2). e61–e64. 2 indexed citations

16.

Gross, Cary P., Jessica B. Long, Joseph S. Ross, et al.. (2013). The Cost of Breast Cancer Screening in the Medicare Population. JAMA Internal Medicine. 173(3). 220–220. 50 indexed citations

17.

Sinclair, Natalie, Maysa Abu‐Khalaf, Tina Rizack, et al.. (2012). Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.. Journal of Clinical Oncology. 30(15_suppl). 1045–1045. 8 indexed citations

18.

Rizack, Tina, Maysa Abu‐Khalaf, Robert D. Legare, et al.. (2010). Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data.. Journal of Clinical Oncology. 28(15_suppl). e11010–e11010. 2 indexed citations

19.

Hazin, Ribhi, et al.. (2009). Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Current Opinion in Ophthalmology. 20(4). 308–317. 22 indexed citations

20.

Abu‐Khalaf, Maysa, Keita Ebisu, Gina G. Chung, et al.. (2005). Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer. Oncology. 69(5). 372–383. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact